

1 **Multi-omics data integration to identify metabolism pathways and therapeutic targets for**
2 **cardiac disease**

3

4 **Authors and affiliations**

5 Sophie C. de Ruiter, MSc¹, Marion van Vugt, MSc^{2,3,4}, Chris Finan, PhD^{3,4,5,6}, Rui Providencia,
6 MD PhD^{6,7}, Sandesh Chopade, MSc^{3,5}, Diederick E. Grobbee, PhD¹, Hester M. den Ruijter, PhD⁸,
7 Sanne A.E. Peters, PhD^{1,9,*}, A. Floriaan Schmidt, PhD^{2,3,4,5,*}

8

- 9 1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,
10 Utrecht University, Utrecht, the Netherlands
- 11 2. Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University
12 Medical Centres, University of Amsterdam, Amsterdam, the Netherlands
- 13 3. Institute of Cardiovascular Science, Faculty of Population Health, University College
14 London, London, United Kingdom
- 15 4. Division Heart and Lungs, Department of Cardiology, University Medical Center Utrecht,
16 Utrecht University, Utrecht, the Netherlands
- 17 5. UCL British Heart Foundation Research Accelerator, London, United Kingdom
- 18 6. Health Data Research UK and Institute of Health Informatics, University College London,
19 London, United Kingdom
- 20 7. Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, United
21 Kingdom
- 22 8. Laboratory of Experimental Cardiology, Division Heart and Lungs, University Medical
23 Center Utrecht, Utrecht University, Utrecht, the Netherlands
- 24 9. The George Institute for Global Health, School of Public Health, Imperial College
25 London, London, UK

26 * joint senior author

- 1 Running title: Therapeutic targets and metabolic pathways for cardiac disease
- 2 Word count text: 4460
- 3 Word count abstract: 257
- 4 Number of references: 54
- 5 Number of tables and figures: 7
- 6 Number of (web) appendices: 2
- 7

1 **Abstract**

2 **Introduction:** Urinary breakdown products, representing kidney regulated filtration of metabolism
3 end products, contain cardiac disease biomarkers such as NT-proBNP. We set out to integrate plasma
4 proteins with metabolism pathways, as reflected by urinary breakdown products, to identify
5 potentially druggable metabolism pathways for cardiac disease.

6 **Methods:** Data was leveraged from a genome-wide association study (GWAS) on 954 urinary
7 breakdown products. Mendelian randomisation was used to identify urinary breakdown products
8 associating with atrial fibrillation (AF), heart failure (HF), dilated cardiomyopathy (DCM), or
9 hypertrophic cardiomyopathy (HCM). By interrogating eight independent plasma protein GWAS,
10 jointly including 92,277 participants and 1,562 unique proteins, we identified druggable plasma
11 proteins with a directionally concordant effect on urinary breakdown products and cardiac outcomes.

12 **Results:** In total, 38 unique urinary breakdown products associated with cardiac disease,
13 predominantly covering breakdown products from amino acid metabolism (n=12), xenobiotic
14 metabolism (n=5), and unclassified metabolism origins (n=16). Subsequently, we identified 32
15 druggable proteins expressed in cardiac tissue, which had a directionally concordant association with
16 the identified urinary breakdown products and cardiac outcomes. This included positive control
17 findings, for example higher values of AT1B2 (targeted by digoxin) decreased the risk of HCM, which
18 we were able to link to a novel unclassified urinary breakdown product (X-15497). Additionally, we
19 showed that increased plasma RET values, a mediator of GDF-15 signalling, reduced the risk of HF,
20 and linked this to the novel unclassified urinary breakdown product X-23776.

21 **Conclusion:** We have identified amino acid, xenobiotic and unclassified metabolism as important
22 pathways contributing to cardiac disease and prioritised 32 druggable proteins as potential therapeutic
23 targets.

24

1 **Introduction**

2 Heart failure (HF) and atrial fibrillation (AF) are cardiac diseases which manifest as ventricular and
3 atrial dysfunction, respectively. While AF frequently affects people without established HF, in people
4 with HF an AF diagnosis often signals early progressive HF, where ventricular dysfunction has an
5 early knock-on effect on atrial rhythm and output. People with hypertrophic cardiomyopathies (HCM),
6 a subtype of HF characterized by an abnormally large and stiff cardiac septum, which may limit
7 cardiac output and affect diastolic function, are particularly susceptible to develop AF. Aside from
8 HCM, dilated cardiomyopathy (DCM) represents a second major non-ischemic HF subtype, where the
9 left ventricle becomes enlarged and thin, limiting cardiac contractility. As such, AF and HF are closely
10 interrelated diseases, with specific underlying pathologies like HCM and DCM playing distinct roles
11 in their manifestation.

12
13 Aside from N-terminal prohormone of brain natriuretic peptide (NT-proBNP), which associates with
14 HF and AF progression(1-3), there is paucity of biomarkers to assist medical practitioners in tailored
15 treatment management, diagnosis, and prognosis. NT-proBNP, which is secreted by cardiomyocytes
16 (cardiac cells responsible for contraction), can be measured in both blood plasma and urine,
17 illustrating the interface between cardiac tissue processes, blood, and urine. Urine biomarkers provide
18 a non-invasive measurement of potential causal metabolic changes reflecting disease onset and
19 progression. While urinary breakdown products represent by-products cleared from plasma, the source
20 of these breakdown products may reflect pathophysiological changes in tissues such as the cardiac
21 muscle. Cardiac function and kidney function are intertwined, through for example the renin-
22 angiotensin-aldosterone system, and the concept of cardiorenal syndrome has been implemented to
23 describe disorders involving both organs, with dysfunction in one organ causing acute or chronic
24 dysfunction in the other(4, 5). Urinary breakdown products are therefore a potentially important
25 source of non-invasive disease markers, which may unveil upstream involvement of biological
26 pathways relevant for cardiac progression and/or novel cardiac therapeutics.

27

1 Recently, availability of affordable, high-throughput assays capable of measuring hundreds of proteins
2 and metabolites has facilitated their analysis in large sample size genome wide association studies
3 (GWAS). Given that proteins form the main constituents of drug targets, GWAS on protein values
4 provide an invaluable resource to identify potential drug targets through genomics tools such as
5 Mendelian randomisation (MR). Utilizing MR, one can infer the effect of an exposure (e.g. a
6 breakdown product or protein) on the risk of disease, by identifying genetic variants strongly
7 associated with the exposure, and determining whether there is a dose-response relationship between
8 the genetic associations with the exposure and the genetic associations with disease(6, 7). Given that
9 genetic variants are fixed at gametogenesis, genetic evidence is robust against bias due to confounding
10 or reverse causation(8, 9). These principles have been extensively validated in the context of
11 cardiovascular disease(10-13), including in a recent study on the effects of plasma proteins on cardiac
12 function and structure(14).

13

14 Although urinary breakdown products are important markers of potential disease mechanisms, they
15 are not directly actionable because they have already been excreted. Plasma proteins are however still
16 actionable and are the main constituents of drug targets. Therefore, we integrated information from
17 urinary metabolism breakdown products to identify metabolism pathways relevant for cardiac disease
18 and information from plasma proteins to identify drug targets that may be used to intervene in these
19 pathways.

20

21 In the current manuscript we used MR to analyse urinary metabolism breakdown products to identify
22 metabolism pathways with possible involvement with four cardiac disease traits: AF, HF, DCM, and
23 HCM. Subsequently, we sought to establish potential plasma protein intermediates by identifying
24 proteins associating with urinary breakdown product values, as well as with cardiac disease risk. The
25 Human Protein Atlas (HPA) was consulted to identify proteins expressed in cardiac tissue, providing
26 further support for cardiac involvement. The subset of proteins expressed in cardiac tissue were
27 subsequently mapped to biological pathways, with druggability determined through linkage with
28 ChEMBL.

1

2 **Methods**

3

4 **Available data**

5 We used a GWAS on 954 urinary breakdown products, which were identified and quantified among
6 1,627 individuals using a non-targeted mass spectrometry assay provided by Metabolon(15). This
7 untargeted approach allows for comprehensive detection of breakdown products, including those of
8 unknown origin. Breakdown products were categorised based on the metabolic origin of the urinary
9 breakdown products: amino acids, carbohydrates, cofactors and vitamins, energy, lipids, nucleotides,
10 peptides, xenobiotics, and unclassified. Xenobiotic breakdown products - substances not naturally
11 produced by the human body, include breakdown products from drugs, environmental pollutants, and
12 various synthetic compounds. Unclassified breakdown products represent potentially novel
13 biomarkers, as they have not yet been related to an established metabolic origin. These breakdown
14 products were noted for their recurring chromatographic and spectral properties and have been
15 assigned unique COMP-IDs and/or CHEM-IDs (**Supplementary Table S1**), which allows for
16 identification and comparison in future studies and by other analysis platforms. Genetic associations
17 with plasma protein values were available from the eight GWAS, detailed in Supplementary Note 1.
18 Genetic associations with cardiac disease onset were available from Nielsen *et al.* (60,620 AF
19 cases)(16), from Shah *et al.* (47,309 HF cases)(17), from Garnier *et al.* (2,719 DCM cases)(18), and
20 from Zhou *et al.* (2,993 HCM cases)(19). Study specific participants characteristics and case/control
21 definitions are described in Supplementary Note 1. All studies obtained informed consent from
22 participants and complied with the Declaration of Helsinki.

23

24 **Mendelian randomisation analyses**

25 Three MR analyses were conducted: 1) genome-wide MR identifying metabolism pathways which, as
26 reflected by urinary breakdown products, associate with onset of cardiac disease (step 1 **Figure 1**,
27 **Appendix Tables S1, S2**), 2) *cis*-MR identifying plasma proteins affecting values of urinary
28 breakdown products (step 2 **Figure 1**), and 3) *cis*-MR identifying plasma proteins which associate

1 with the onset of cardiac disease (step 3 **Figure 1**). In the genome-wide MR we selected genetic
2 variants from across the genome, while in the *cis*-MR genetic variants were selected from a 200
3 kilobase pair window around and within the protein encoding gene. In both cases, variants were
4 selected based on an exposure F-statistic of at least 24 and a minor allele frequency of 0.01 or larger.
5 The remaining variants were clumped to a linkage disequilibrium (LD) r-squared of 0.30, based on a
6 random 5,000 sample of unrelated UK Biobank participants. The *cis*-MR analyses (steps 2-3 **Figure**
7 **1**) were conducted per individual protein GWAS, where the largest sample size GWAS was used in
8 the case of overlap in measured proteins.

9

10 MR analyses were conducted using generalized least squares (GLS) implementations of the inverse
11 variance weighted (IVW) estimator, as well as the pleiotropy robust MR-Egger estimator(20). The
12 GLS implementation was used to additionally correct for residual LD, which optimized estimator
13 precision(21). To reduce the potential for horizontal pleiotropy, we excluded variants with large
14 leverage statistics (larger than three times the mean leverage) and/or outlier statistics (Chi-square
15 larger than 10.83). Analyses with fewer than 6 variants as instrument were discarded to ensure we had
16 sufficient data to accurately model the exposure effects. The potential influence of horizontal
17 pleiotropy was further minimized by applying a model selection framework identifying the MR model
18 (IVW or MR-Egger) most supported by the available data (Supplementary Note 1).

19

20 **Effect estimates and multiple testing**

21 MR results are presented as mean differences (MD) for continuous outcomes, or odds ratios (ORs) for
22 binary outcomes, representing the effect of an SD increase of the exposure (i.e., either urinary
23 breakdown product or plasma protein value). Effect estimates are not constrained to be positive (i.e.,
24 they can indicate an increase or decrease in the outcome) and are accompanied by 95% confidence
25 intervals (CIs) and p-values. Breakdown product effects on disease were filtered for a multiplicity
26 corrected p-value threshold of 1.37×10^{-7} based on the 365 principal components that were needed to
27 explain 90% of the urinary breakdown product variance (**Appendix Figure S1**). Protein MR effect
28 estimates were evaluated against a multiplicity corrected p-value of 8.42×10^{-7} for the breakdown

1 products, based on the number of tested proteins (n=1,562) and breakdown products (n=38). The
2 multiplicity corrected p-value was 1.76×10^{-5} for cardiac outcomes, based on the number of tested
3 proteins (n=709) and outcomes (n=4). Proteins are referred to using their Uniprot label(22), while
4 genes are referred to using their Ensembl label in italicised font.

5

6 **Triangulation of evidence through consideration of concordant cardiac effects**

7 The three distinct MR analyses were integrated by I) identifying urinary breakdown products affecting
8 cardiac disease, II) identifying whether there were proteins associated with these urinary breakdown
9 products, and III) focussing on the subset of proteins with a directionally concordant effect on the
10 same cardiac disease trait the urinary breakdown products associated with. For example, if a higher
11 value of a urinary breakdown product decreased the risk of HF, and the protein increased the urinary
12 breakdown product value, the protein effect was considered directionally concordant if in turn higher
13 protein values decreased HF risk. Conversely, if a higher value of a urinary breakdown product
14 increased the risk of HF, and the protein decreased the urinary breakdown product value, the protein
15 effect would still be considered directionally concordant if higher protein values decreased HF risk.
16 When all these conditions are met – directional concordance between the protein, breakdown product,
17 and cardiac outcome – we describe this as a triangulated association (**Figure 2**). We note that because
18 each performed MR analysis makes a distinct, and independent, assumption on the absence of
19 horizontal pleiotropy, focusing on the directionally concordant results is anticipated to identify a
20 robust subset of analyses with limited influence of potential horizontal pleiotropy.

21

22 **Prioritisation of proteins expressed in cardiac tissue**

23 The set of proteins with a triangulated effect on breakdown product and cardiac outcome were
24 subsequently prioritised for the presence of cardiac tissue mRNA expression, differentiating between
25 proteins with general cardiac expression, and proteins which were overexpressed (Supplementary Note
26 1). We also tested for overexpression in other tissues, providing greater context regarding the type of
27 protein.

28

1 **Annotation of prioritised proteins**

2 We identified plasma proteins targeted by approved drugs (drugged proteins), as well as potentially
3 druggable proteins based on ChEMBL-v33. For the drugged and druggable proteins, we additionally
4 extracted compound indications and side-effects, sourcing information from ChEMBL and the British
5 National Formulary (BNF, access date September 4, 2021). Finally, all proteins available in the
6 considered GWAS were mapped to biological pathways using the Reactome knowledgebase-v85(23)
7 and prioritised proteins (combined irrespective of cardiac or metabolite class association, as well as,
8 stratified by cardiac disease, or stratified by metabolite class) were tested for enrichment against the
9 full set of 1,567 proteins.

10

11 **Partial replication of protein associations with cardiac traits**

12 Due to the availability of 8 proteomics GWAS, some studies assayed the same proteins, which we
13 leveraged to replicate our findings, specifically focussing on associations with cardiac traits.
14 Replication was sought using a nominally significant p-value of 0.05 or smaller and considering the
15 effect direction of the triangulated analysis. In addition, a more stringent p-value threshold of 8.93×10^{-4}
16 (0.05 divided by the number of proteins available in more than one study) was used for more
17 conservative replication.

18

19 **Results**

20

21 **Urinary breakdown products associating with the onset of cardiac disease**

22 We conducted Mendelian randomisation to identify urinary breakdown products linked to cardiac
23 disease, unveiling potential non-invasive biomarkers and altered metabolism pathways involved in
24 cardiac disease progression. Out of 954 evaluated urinary breakdown products (**Appendix Table S1**),
25 38 breakdown products were found to be associated with at least one type of cardiac disease: 25 for
26 AF, 11 for HF, 5 for DCM, and 14 for HCM (step 1 **Figure 1**, **Appendix Tables S2, S3**, **Figure 3**).
27 Urinary breakdown products were frequently associated with AF, where particularly amino acid and
28 xenobiotic breakdown products associated with cardiac diseases. For example, higher values of 1-

1 methylhistamine increased the risk of HF (OR 1.07, 95% CI 1.05; 1.09), while decreasing the risk of
2 AF (OR 0.83, 95% CI 0.76; 0.90). Higher values of 1-methylxanthine, a xenobiotic breakdown product
3 of caffeine, decreased the risk of AF, DCM, and HCM (**Appendix Table S2, Figure 3**). Finally, we
4 were able to associate 16 urinary breakdown products of unknown metabolic origin (unclassified
5 breakdown products) with cardiac disease.

6

7 **Triangulated proteins with concordant effects on urinary breakdown products and cardiac** 8 **diseases**

9 Mendelian randomisation was used to determine associations between plasma proteins and the 38
10 urinary breakdown products associated with cardiac disease. We identified 709 proteins associated
11 with at least one of the 38 urinary breakdown products (step 2 **Figure 1, Appendix Figure S2**). We
12 then used MR to identify which of these proteins also associated with the considered cardiac diseases
13 and identified 235 proteins (step 3 **Figure 1, Appendix Figure S3**). By considering directional
14 concordance and cardiac tissue expression we identified 91 prioritised proteins (step 4 **Figure 1,**
15 **Appendix Tables S4, S5**).

16

17 This prioritised set included 6 proteins which were overexpressed in cardiac tissues on mRNA level
18 (**Figure 4**): TIG1 (affecting urinary breakdown products 1-methylxanthine), DNJA4 (affecting urinary
19 breakdown product X-19141), NAR3 (affecting urinary breakdown products n-acetylcitrulline, 4-
20 guanidinobutanoate, and X-23776), SPT20 (affecting urinary breakdown products 1-methylhistamine
21 and X-19141), GLO2 (affecting urinary breakdown products n-methylpipercolate and 3-
22 hydroxyindolin-2-one sulfate), and PLXA1 (affecting urinary breakdown products 1-methylhistamine,
23 glycocholate sulfate, and 1-methylxanthine) (**Appendix Table S4**). Besides their overexpression in
24 cardiac tissue, these proteins were also overexpressed in at least one other tissue in the body, such as
25 the skeletal muscle and ovaries (**Appendix Table S4**).

26

27 **Drugged and druggable prioritised proteins**

1 We sourced ChEMBL and BNF to determine druggability of the prioritised proteins. The set of 91
2 prioritised proteins included 20 drugged proteins, and 12 druggable proteins (step 4 **Figure 1**). The 20
3 drugged proteins included seven positive control proteins where the drug indication matched the MR
4 disease association (ACES, EGLN1, ICAM1, NQO2, RET, TRY3, and UD11). For example, we
5 showed that higher levels of ACES increased the risk of both AF and HF, mimicking the protective
6 effect of ACE inhibitor drugs. Furthermore, we identified six proteins targeted by a drug indicated for
7 a cardiac disease distinct from the MR associations (MANBA, NQO1, NTRK3, OLA1, TEC, and
8 TRYB1), identifying compounds relevant for rapid drug repositioning. For example, MANBA is
9 targeted by migalastat used to treat GLA amenable Fabry disease, where the MR analysis supported
10 potential repositioning to treat AF. Additionally, we identified three proteins (AT1B2, DPEP1, and
11 MET) targeted by drug compounds with a registered cardiac side-effect which may be relevant for
12 drug repurposing. Finally, four proteins were targeted by drug compounds without a cardiac indication
13 or side effect, providing further opportunities for drug repurposing. For example, ADH1B (associated
14 with HF) is targeted by nitrefazole which is used to treat alcohol addiction (**Table 1, Figure 5,**
15 **Appendix Tables S7, S8**).

16
17 Irrespective of the known side effects or indications, the identified proteins frequently associated with
18 AF, with many of these proteins (partially) acting through xenobiotic (n=8) and amino acid (n=6)
19 metabolism (**Figure 5**). Specifically, GLO2, ACES, EGLN1 (OR 0.88, 95% CI 0.84; 0.92), LYAM2,
20 IBP3, and ENTP5 affected AF and associated with xenobiotic breakdown product values. Similarly,
21 DPEP1 (OR 0.97, 95% CI 0.96; 0.98), TRYB1, HEX11, and TEC (OR 0.87, 95% CI 0.83; 0.90)
22 affected AF and associated with amino acid breakdown product values. Higher values of TRY3 (OR
23 0.92, 95% CI 0.90; 0.94) and NAGK decreased AF risk and associated with both amino acid and
24 xenobiotic breakdown products values.

25
26 Most proteins affecting HF associated with unclassified metabolism pathways (n=7). Specifically,
27 increased values of ACES, RET (OR 0.97, 95% CI 0.96; 0.98), ADH1B, ERAP1 (OR 0.97, 95% CI

1 0.96; 0.98), FCG2A, NQO1, and CTGF affected HF risk and also associated with unclassified urinary
2 breakdown products.

3

4 Similarly, drugged and druggable proteins affecting HCM predominantly associated with unclassified
5 metabolism pathways (n=5). Specifically, higher values of ICAM1, NTRK3, CAN2, SIGL7, and
6 AT1B2 affected HCM risk.

7

8 For DCM we identified three drugged or druggable proteins with higher values of UD11 and CATA
9 increasing DCM risk and associating with peptide breakdown product prolylglycine, and higher values
10 of PLA2R (OR 0.92, 95% CI 0.91; 0.94) decreasing DCM risk and associating with xenobiotic
11 breakdown product N-methylpipercolate.

12

13 **Triangulated proteins with an effect on multiple cardiac traits**

14 We additionally identified eleven pleiotropic proteins associated with multiple cardiac outcomes. Most
15 of these were associated with unclassified and xenobiotic urinary metabolism breakdown products.

16 Specifically, ACES, PLXB2, PLXA1, CYTF, and GNPTG affected AF and HF (**Figure 6**). ICAM1,
17 MICB, and EVA1C affected both HCM and HF, while MATN3 and ACYP2 affected HCM and AF,
18 while PLA2R affected HCM and DCM (**Figure 6, Appendix Table S6**).

19

20 **Proteins enriched in biological pathways**

21 Based on the Reactome knowledgebase, we found the “antigen presentation: folding, assembly and
22 peptide loading of class I MHC” pathway to be enriched among the triangulated proteins. This
23 pathway involved proteins TPSN (associated with HCM) and ERAP1 (associated with HF)

24 (**Appendix Tables S6, S9**). Enriched pathways in the subset of prioritised proteins per metabolite
25 class and per disease outcome are indicated in **Appendix Figure S4** and **S5**.

26

27 **Replication of protein effects on cardiac outcomes**

1 Of the 91 prioritised proteins associating with one or more cardiac traits 56 were available in more
2 than a single study, applying a nominal 0.05 p-value threshold this resulted in a replication of 47
3 (84%) protein associations with cardiac disease. Applying a multiplicity corrected threshold resulted
4 in 37 (66%) replicated proteins (**Appendix Table S10**). Replication results for protein effects on
5 breakdown product values are described in Supplementary Note 1 (**Appendix Table S11**).

6

7 **Discussion**

8 In this study, we used Mendelian randomisation to assess relationships between 954 urinary
9 breakdown products, 1,562 proteins, and four cardiac diseases AF, HF, DCM, and HCM. We found
10 directionally concordant associations between 38 breakdown products, 91 cardiac expressed proteins,
11 and the considered cardiac diseases. The urinary breakdown products are potential biomarkers of
12 altered metabolism pathways informative of the aetiology and consequences of cardiac diseases, and
13 the plasma proteins may be used as drug targets to intervene in these metabolism pathways.

14

15 The identified urinary breakdown products associating with cardiac disease predominantly included
16 breakdown products with an origin in amino acids metabolism, xenobiotics metabolism, and of
17 unclassified metabolism. Of the 91 proteins, six were overexpressed in cardiac tissue. We additionally
18 identified eleven pleiotropic proteins with an effect on more than one cardiac outcome. Furthermore,
19 20 proteins were targeted by an approved drug, which included seven positive control proteins that
20 were targeted by a compound with a cardiac indication matching the MR disease association (ACES,
21 EGLN1, ICAM1, NQO2, RET, TRY3, and UD11), as well as six targets for drugs with a cardiac
22 indication distinct from the MR disease association (MANBA, NQO1, NTRK3, OLA1, TEC, and
23 TRYB1), and three targets for drugs with a known cardiovascular side-effect (AT1B2, DPEP1, and
24 MET) which may be relevant for drug repurposing. For example, we found that the approved
25 compounds nitrofurantoin and arginine may be beneficially repurposed to treat HF or AF, respectively.
26 Future studies may consider analysis of available (nationwide) prescription data to provide further
27 evidence of efficacy, which may be confirmed by more time consuming and costly randomised
28 controlled trials.

1

2 We identified seven amino acids breakdown products associated with AF of which six
3 (cysteinylglycine disulfide, 4-guanidinobutanoate, N-acetylcitrulline, N-acetyl-3-methylhistidine, N-
4 acetylarginine, and N-acetylasparagine) increased the risk of AF, corroborating previous observations
5 of altered amino acid metabolism in AF patients(24). We found 27 proteins associated with these
6 amino acids and AF, including 7 drugged or druggable proteins. For example, we showed that higher
7 values of MANBA (mannosidase beta) increased AF risk, which is supported by recent GWAS
8 associating genetic variants near *MANBA* with AF(25) and by two recent MR studies identifying
9 *MANBA* as a potential drug target for AF with corresponding effect directions(26, 27). *MANBA* is
10 targeted by migalastat, a drug used to treat Fabry disease(28), which closely resembles HCM(29), with
11 patients often suffering from cardiac arrhythmias and conduction tissue infiltration, leading to
12 electrical instabilities. An observational study on Fabry disease patients revealed that atrial function
13 was better preserved in those treated with migalastat compared to untreated individuals(30). Through
14 our analyses of urinary breakdown products, we were able to link *MANBA* to fatty acid metabolism
15 through nonenedioate, with faulty fat metabolism a canonical characteristic of Fabry disease(31).
16 Jointly, this suggest *MANBA* may offer therapeutic potential for treatment of AF and related
17 arrhythmias through altered lipid metabolism. These insights not only improve our understanding of the
18 metabolic origins of atrial fibrillation but also highlight *MANBA* as a promising target for
19 intervention. The potential to repurpose migalastat or develop new therapies targeting *MANBA* offers
20 a novel approach for AF treatment, potentially relevant in patients with metabolic disturbances similar
21 to those observed in Fabry disease. Additionally, we found that higher levels of *MET* are associated
22 with reduced AF risk. *MET* is targeted by crizotinib, a cancer drug which has side-effects including
23 arrhythmias. Previous research also identified *MET* as target with repurposing potential for AF
24 treatment(32).

25

26 We identified eleven urinary breakdown products associating with HF which included five breakdown
27 products with an origin in amino acids metabolism and five with an unclassified origin. We were able
28 to map these to 27 plasma proteins with a directionally concordant HF effect, which included MICB

1 (MHC class I polypeptide-related sequence B). MICB increased the risk of both HF and HCM, and
2 was linked to seven yet unclassified breakdown products. This closely aligns with our pathway
3 enrichment analysis identifying MHC class I related pathways implicated in HCM (based on protein
4 TPSN) and HF (based on protein ERAP1), which are linked to CD8+ T-cell mediated cardiac
5 remodelling(33), underscoring the potential role of immune modulation in the pathogenesis of these
6 conditions. While these proteins are not yet druggable, our analysis did identify ICAM1 (associating
7 with HCM and HF), RET and NQO2 (both associating with HF), which have already been drugged.
8 Through consideration of urinary breakdown products we were able to associate ICAM1 with 1-
9 methylxanthine and X-18889, where the former is a breakdown product of xanthine, and the oxidation
10 of xanthine has been linked to ICAM1 neutrophil binding capacity(34). Notably, immune cell
11 activation, reflecting systemic but low-grade inflammation, is a likely key pathophysiologic process
12 progressing towards HCM, other cardiomyopathies, and end-stage HF(35). Regorafenib, a RET
13 inhibiting drug that is used for cancer treatment, has registered side effects including myocardial
14 ischemia and hypertension. These side effects support our findings that lower values of RET are
15 associated with a higher risk of HF onset, where the unclassified urinary breakdown product X-23776
16 was involved in the triangulated association. The GDNF family receptor α -like (GFRAL) acts a
17 receptor for GDF15, which signals through the RET co-receptor. GDF15 was found to be relevant for
18 energy homeostasis and has been identified as a biomarker of cardiovascular and metabolic diseases.
19 There is potential for a new class of drugs based on GDF15-GFRAL-RET, where the signalling
20 pathway is modified(36). Additionally, GDF15 has been recognized as an indicator for HF risk and
21 prediction of hospitalisation for HF or all-cause mortality before(37). The protein NQO2 was
22 associated with a decreased risk of HF, through the amino acid breakdown product
23 indoleacetylglutamine. Prazosin, which acts as an adrenergic receptor alpha-1 antagonist and targets
24 NQO2, has shown potential benefits for HF patients in previous observational studies and trials(38,
25 39), suggesting prazosin might be a relevant repurposing candidate for HF.
26
27 We found five urinary breakdown products and eight proteins associated with DCM risk, including
28 three drugged or druggable proteins, underscoring their potential clinical relevance. For example, we

1 showed that increased values of UD11 increased the risk for DCM and reduced the values of the
2 peptide breakdown product prolylglycine. UD11 is targeted by beta-blockers carvedilol and labetalol
3 (used for HF, hypertension, coronary artery disease and myocardial ischemia), by the diuretics
4 furosemide and bumetanide (used for HF and hypertension) and by acetazolamide, which is not used
5 in practice but has shown benefits in acute decompensated heart failure in a previous clinical trial(40).
6 These findings suggest that modulation of UD11 could be a viable therapeutic strategy in reducing the
7 risk of DCM, providing a rationale for further investigation of UD11 as drug target for treatment for
8 individuals at risk of DCM.

9

10 We note that 13 prioritised proteins affected xenobiotic urinary breakdown product values, indicating
11 that these proteins affect xenobiotic metabolism and excretion. For example, we found that ICAM1
12 associates with the urinary breakdown product value of xenobiotic 1-methylxanthine. This is in line
13 with previous findings indicating that increased expression of ICAM1, which is present on the
14 leukocytes (as well as endothelial cells), facilitates phagocytosis of xenobiotics(41-43).

15

16 Despite the robustness of combining multiple MR analyses sourcing various GWAS on both proteins
17 and breakdown products, there are some potential limitations that we wish to discuss. First of all, the
18 genetic data we used was sourced from multiple GWAS which used various high throughput assays,
19 varying in accuracy and analytic scope(44). Instead of directly measuring concentrations, these assays
20 evaluate relative values of proteins or breakdown products. Hence, the magnitude of association is
21 difficult to interpret, and potential follow-up studies are needed to explore compound specific
22 pharmacokinetic and pharmacodynamic properties. Our current analysis predominantly provides
23 information on the putative drug mechanism and whether compounds should be inhibitory or
24 activating. In addition, associations between urinary breakdown products and cardiac disease should
25 not be misinterpreted as implying that urinary breakdown products themselves have a causal effect on
26 disease. Rather we use urinary breakdown products as a proxy for more distal metabolic processes,
27 such as those occurring in or impacting cardiac tissue. Due to relying on aggregate data instead of
28 individual patient data, we could not explore potential influence of variant by environment

1 interactions, for example due to differences in sex or fasting state. However, genetic variants are
2 determined at gametogenesis and therefore MR is protected against most forms of confounding
3 reflecting the presence of a common cause of the genetic variant and the outcome or exposure. Even in
4 the presence of variant by environment interaction, our triangulation approach prioritises results where
5 these interactions are either absent or of minimal importance. This makes our approach conservative,
6 potentially overlooking a number of true associations, but the associations we do identify are robust
7 against environmental influences, which is also indicated by the high degree of replication.
8 Furthermore, GWAS data were mainly obtained from European cohorts, which may limit
9 generalizability to non-European populations. Finally, while we had access to a large sample size
10 GWAS on HF (47,309 cases), we did not have information on HF subtypes, and future studies
11 considering HF subtypes may yield additional insights.

12

13 Examining the associations between urinary breakdown products, cardiac disease and proteins in a
14 triangulated way provides a comprehensive and robust analysis. Concordance in results from all three
15 analyses – which are based on distinct sources of data – indicate a more reliable effect. Discordant
16 results however do not necessarily indicate invalid MRs but are potentially indicative of a limited
17 influence of the protein on the metabolism process influencing cardiac disease, or may reflect more
18 intricate biological processes.

19

20 In conclusion, 38 metabolism pathways and 91 proteins were identified for involvement with cardiac
21 disease, providing important evidence to support drug development of novel and repurposing targets.
22 Additionally, our manuscript illustrates the value of integrating multi-modal sources of evidence to
23 identify information potentially relevant for disease diagnosis, prognosis, and aetiology.

24

1 **Funding:** SD and SAEP are supported by a VIDI Fellowship (project number 09150172010050) from
2 the Dutch Organisation for Health Research and Development (ZonMW) awarded to SAEP. AFS is
3 supported by BHF grant PG/22/10989, the UCL BHF Research Accelerator AA/18/6/34223,
4 MR/V033867/1, the National Institute for Health and Care Research University College London
5 Hospitals Biomedical Research Centre, and the EU Horizon scheme (AI4HF 101080430 and
6 DataTools4Heart 101057849). This work was supported by the NWO Snellius supercomputer project
7 (application 2023.022).

8

9 **Role of funders:** The funding source did not influence the study design, the collection, analysis, and
10 interpretation of data, the writing of the report, or the decision to submit the manuscript for
11 publication.

12

13 **Acknowledgements:** A preprint version of this manuscript has been deposited at:
14 <https://doi.org/10.1101/2024.02.27.24303421>. This research has been conducted using the UK
15 Biobank Resource under Application Number 12113. The authors are grateful to UK Biobank
16 participants.

17

18 **Declaration of competing interests:** AFS and CF have received funding from New Amsterdam
19 Pharma for unrelated projects. The other authors declare that they have no conflict of interest.

20

21 **Author contributions:** SD, AFS, and SP designed the study. SD and MV accessed the data, verified
22 the data, and performed analyses. SD drafted the manuscript. All authors provided critical input on the
23 analysis, as well as the drafted manuscript.

24

25 **Code availability:** Analyses were conducted using Python v3.7.13 (for GNU Linux), Pandas v1.3.5,
26 Numpy v1.21.6, bio-misc v0.1.4, and matplotlib v3.4.3. Code to reproduce figures and tables will be
27 made available upon publication. Genetic summary-level data underpinning each individual MR
28 analysis will be made available at Figshare upon publication.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Data availability: The individual GWAS data on cardiac outcomes leveraged in this study can be accessed as follows: atrial fibrillation (cases=60,620, total n=1,030,836; <https://www.ebi.ac.uk/gwas/publications/30061737>), heart failure (cases=47,309, total n=977,323; <https://www.ebi.ac.uk/gwas/publications/31919418>), dilated cardiomyopathy (cases=2,719, total n=6,980; <https://www.ebi.ac.uk/gwas/publications/33677556>) and hypertrophic cardiomyopathy (cases=2,993, total n=1,197,200; <http://results.globalbiobankmeta.org/pheno/HCM>). The GWAS data on urinary breakdown product values can be accessed via <https://www.ebi.ac.uk/gwas/publications/31959995> (n=1,627). The individual GWAS data on plasma protein values can be accessed as follows: deCODE (n=35,559, <https://www.decode.com/summarydata/>), SCALLOP (n=30,931, <https://www.ebi.ac.uk/gwas/publications/33067605>), Ahola-Olli et al. (n=8,293, <https://www.ebi.ac.uk/gwas/publications/27989323>), Framingham (n=6,861, <https://www.ebi.ac.uk/gwas/publications/21909115>), AGES-Reykjavik (n=5,368, <https://www.ebi.ac.uk/gwas/publications/35078996>), INTERVAL (n=3,301, <https://www.ebi.ac.uk/gwas/publications/29875488>), Gilly et al. (n=1,328, <https://www.ebi.ac.uk/gwas/publications/33303764>), and Yang et al. (n=636, <https://www.ebi.ac.uk/gwas/publications/34239129>).

1 References

- 2 1. Cortés R, Portolés M, Salvador A, Bertomeu V, de Burgos FG, Martínez-Dolz L, Lletí ER,
3 Climent V, Jordán A, Payá R. Diagnostic and prognostic value of urine NT-proBNP levels in heart
4 failure patients. *European journal of heart failure*. 2006;8(6):621-7.
- 5 2. Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G,
6 Pyrgakis V, W Cleman M. NTproBNP: an important biomarker in cardiac diseases. *Current topics in*
7 *medicinal chemistry*. 2013;13(2):82-94.
- 8 3. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction
9 in both clinical and forensic medicine. *International journal of molecular sciences*. 2019;20(8):1820.
- 10 4. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and
11 pharmacologic inhibition. *Journal of managed care pharmacy*. 2007;13(8 Supp B):9-20.
- 12 5. Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K,
13 Molitch M, Mullens W. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and
14 treatment strategies: a scientific statement from the American Heart Association. *Circulation*.
15 2019;139(16):e840-e78.
- 16 6. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B,
17 Chopade S, Faraway R, Zwierzyzna M. Genetic drug target validation using Mendelian randomisation.
18 *Nature communications*. 2020;11(1):1-12.
- 19 7. Schmidt AF, Hingorani AD, Finan C. *Human Genomics and Drug Development*. Cold Spring
20 *Harb Perspect Med*. 2022;12(2).
- 21 8. Hingorani A, Humphries S. Nature's randomised trials. *The Lancet*. 2005;366(9501):1906-8.
- 22 9. de Ruiter SC, Schmidt AF, Grobbee DE, den Ruijter HM, Peters SA. Sex-specific Mendelian
23 randomisation to assess the causality of sex differences in the effects of risk factors and treatment:
24 Spotlight on hypertension. *Journal of Human Hypertension*. 2023:1-7.
- 25 10. Cupido AJ, Asselbergs FW, Natarajan P, Group CIW, Ridker PM, Hovingh GK, Schmidt AF.
26 Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both
27 IL6 and IL6R. *British Journal of Clinical Pharmacology*. 2022;88(6):2875-84.
- 28 11. Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurler MR, Gutteridge A, Erola P,
29 Liu Y, Luo S. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome
30 on complex diseases. *Nature genetics*. 2020;52(10):1122-31.
- 31 12. Schmidt AF, Hunt NB, Gordillo-Marañón M, Charoen P, Drenos F, Kivimaki M, Lawlor DA,
32 Giambartolomei C, Papacosta O, Chaturvedi N. Cholesteryl ester transfer protein (CETP) as a drug
33 target for cardiovascular disease. *Nature communications*. 2021;12(1):5640.
- 34 13. Consortium I-RMRA. The interleukin-6 receptor as a target for prevention of coronary heart
35 disease: a mendelian randomisation analysis. *The Lancet*. 2012;379(9822):1214-24.
- 36 14. Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, van der Laan
37 SW, Gross C, Clarkson C, Henry A. Druggable proteins influencing cardiac structure and function:
38 Implications for heart failure therapies and cancer cardiotoxicity. *Science Advances*.
39 2023;9(17):eadd4984.
- 40 15. Schlosser P, Li Y, Sekula P, Raffler J, Grundner-Culemann F, Pietzner M, Cheng Y, Wuttke
41 M, Steinbrenner I, Schultheiss UT. Genetic studies of urinary metabolites illuminate mechanisms of
42 detoxification and excretion in humans. *Nature genetics*. 2020;52(2):167-76.
- 43 16. Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, Herron TJ,
44 McCarthy S, Schmidt EM, Sveinbjörnsson G. Biobank-driven genomic discovery yields new insight
45 into atrial fibrillation biology. *Nature genetics*. 2018;50(9):1234-9.
- 46 17. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman ÅK, Wilk JB,
47 Morley MP, Chaffin MD. Genome-wide association and Mendelian randomisation analysis provide
48 insights into the pathogenesis of heart failure. *Nature communications*. 2020;11(1):1-12.
- 49 18. Garnier S, Harakalova M, Weiss S, Mokry M, Regitz-Zagrosek V, Hengstenberg C, Cappola
50 TP, Isnard R, Arbustini E, Cook SA. Genome-wide association analysis in dilated cardiomyopathy
51 reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. *European*
52 *Heart Journal*. 2021;42(20):2000-11.

- 1 19. Zhou W, Kanai M, Wu K-HH, Rasheed H, Tsuo K, Hirbo JB, Wang Y, Bhattacharya A, Zhao
2 H, Namba S. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human
3 disease. *Cell Genomics*. 2022;2(10).
- 4 20. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
5 effect estimation and bias detection through Egger regression. *International journal of epidemiology*.
6 2015;44(2):512-25.
- 7 21. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization
8 with fine-mapped genetic data: choosing from large numbers of correlated instrumental variables.
9 *Genetic epidemiology*. 2017;41(8):714-25.
- 10 22. Consortium U. The universal protein resource (UniProt) in 2010. *Nucleic acids research*.
11 2010;38(suppl_1):D142-D8.
- 12 23. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J,
13 Gillespie M, Haw R. The reactome pathway knowledgebase. *Nucleic acids research*.
14 2020;48(D1):D498-D503.
- 15 24. She J, Guo M, Li H, Liu J, Liang X, Liu P, Zhou B, Liu S, Deng Y, Lou B. Targeting amino
16 acids metabolic profile to identify novel metabolic characteristics in atrial fibrillation. *Clinical science*.
17 2018;132(19):2135-46.
- 18 25. Miyazawa K, Ito K, Ito M, Zou Z, Kubota M, Nomura S, Matsunaga H, Koyama S, Ieki H,
19 Akiyama M. Cross-ancestry genome-wide analysis of atrial fibrillation unveils disease biology and
20 enables cardioembolic risk prediction. *Nature genetics*. 2023;55(2):187-97.
- 21 26. Wang X, Huang T, Jia J. Proteome-Wide Mendelian Randomization Analysis Identified
22 Potential Drug Targets for Atrial Fibrillation. *Journal of the American Heart Association*.
23 2023;12(16):e029003.
- 24 27. Ning Z, Huang Y, Lu H, Zhou Y, Tu T, Ouyang F, Liu Y, Liu Q. Novel Drug Targets for
25 Atrial Fibrillation Identified Through Mendelian Randomization Analysis of the Blood Proteome.
26 *Cardiovascular Drugs and Therapy*. 2023:1-8.
- 27 28. McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. *Drugs*. 2019;79:543-54.
- 28 29. Moroni A, Tondi L, Milani V, Pieroni M, Pieruzzi F, Bevilacqua F, Pasqualin G, Chow K,
29 Pica S, Lombardi M. Left atrial remodeling in hypertrophic cardiomyopathy and Fabry disease: A
30 CMR-based head-to-head comparison and outcome analysis. *International Journal of Cardiology*.
31 2023;393:131357.
- 32 30. Pogoda C, Brand S-M, Duning T, Schmidt-Pogoda A, Sindermann J, Lenders M, Brand E.
33 Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in
34 patients with Fabry disease. *Frontiers in Cardiovascular Medicine*. 2023;10.
- 35 31. Li X, Ren X, Zhang Y, Ding L, Huo M, Li Q. Fabry disease: Mechanism and therapeutics
36 strategies. *Frontiers in Pharmacology*. 2022;13:1025740.
- 37 32. Kukendrarajah K, Farmaki A-E, Lambiase PD, Schilling R, Finan C, Schmidt AF, Providencia
38 R. Advancing drug development for atrial fibrillation by prioritising findings from human genetic
39 association studies. *EBioMedicine*. 2024;105.
- 40 33. Komai K, Ito M, Nomura S, Shichino S, Katoh M, Yamada S, Ko T, Iizuka-Koga M,
41 Nakatsukasa H, Yoshimura A. Single-cell analysis revealed the role of CD8+ effector T cells in
42 preventing cardioprotective macrophage differentiation in the early phase of heart failure. *Frontiers in*
43 *Immunology*. 2021;12:763647.
- 44 34. Sellak H, Franzini E, Hakim J, Pasquier C. Reactive oxygen species rapidly increase
45 endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. 1994.
- 46 35. Lillo R, Graziani F, Franceschi F, Iannaccone G, Massetti M, Olivotto I, Crea F, Liuzzo G.
47 Inflammation across the spectrum of hypertrophic cardiac phenotypes. *Heart Failure Reviews*. 2023:1-
48 11.
- 49 36. Rochette L, Dogon G, Zeller M, Cottin Y, Vergely C. GDF15 and cardiac cells: current
50 concepts and new insights. *International Journal of Molecular Sciences*. 2021;22(16):8889.
- 51 37. Bradley J, Schelbert EB, Bonnett LJ, Lewis GA, Lagan J, Osborne C, Brown PF, Black N,
52 Naish JH, Williams SG. Growth differentiation factor-15 in patients with or at risk of heart failure but
53 before first hospitalisation. *Heart*. 2023.
- 54 38. Antani J, Antani NJ, Nanivadekar A. Prazosin in chronic congestive heart failure due to
55 ischemic heart disease. *Clinical cardiology*. 1991;14(6):495-500.

- 1 39. Colucci WS, Wynne J, Holman BL, Braunwald E. Long-term therapy of heart failure with
2 prazosin: a randomized double blind trial. *The American Journal of Cardiology*. 1980;45(2):337-44.
- 3 40. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F,
4 Moubayed S, Dierckx R. Acetazolamide in acute decompensated heart failure with volume overload.
5 *New England Journal of Medicine*. 2022;387(13):1185-95.
- 6 41. Zhong H, Lin H, Pang Q, Zhuang J, Liu X, Li X, Liu J, Tang J. Macrophage ICAM-1
7 functions as a regulator of phagocytosis in LPS induced endotoxemia. *Inflammation Research*.
8 2021;70:193-203.
- 9 42. Wen L, Han Z. Identification and validation of xenobiotic metabolism-associated prognostic
10 signature based on five genes to evaluate immune microenvironment in colon cancer. *Journal of*
11 *gastrointestinal oncology*. 2021;12(6):2788.
- 12 43. Hubbard AK. Effects of xenobiotics on macrophage function: evaluation in vitro. *Methods*.
13 1999;19(1):8-16.
- 14 44. Katz DH, Robbins JM, Deng S, Tahir UA, Bick AG, Pampana A, Yu Z, Ngo D, Benson MD,
15 Chen Z-Z. Proteomic profiling platforms head to head: leveraging genetics and clinical traits to
16 compare aptamer-and antibody-based methods. *Science Advances*. 2022;8(33):eabm5164.
- 17 45. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrismisdottir EL,
18 Gunnarsdottir K, Helgason A, Oddsson A, Halldorsson BV. Large-scale integration of the plasma
19 proteome with genetics and disease. *Nature Genetics*. 2021;53(12):1712-21.
- 20 46. Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, Page K,
21 Zhernakova DV, Wu Y, Peters J. Genomic and drug target evaluation of 90 cardiovascular proteins in
22 30,931 individuals. *Nature metabolism*. 2020;2(10):1135-48.
- 23 47. Ahola-Olli AV, Würtz P, Havulinna AS, Aalto K, Pitkänen N, Lehtimäki T, Kähönen M,
24 Lyytikäinen L-P, Raitoharju E, Seppälä I. Genome-wide association study identifies 27 loci
25 influencing concentrations of circulating cytokines and growth factors. *The American Journal of*
26 *Human Genetics*. 2017;100(1):40-50.
- 27 48. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin
28 MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, et al. Genetic variants
29 in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*.
30 2011;478(7367):103-9.
- 31 49. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ,
32 Lamb JR, Jennings LL, Aspelund T, Emilsson V. A genome-wide association study of serum proteins
33 reveals shared loci with common diseases. *Nature communications*. 2022;13(1):1-13.
- 34 50. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T,
35 Paige E, Surendran P. Genomic atlas of the human plasma proteome. *Nature*. 2018;558(7708):73-9.
- 36 51. Gilly A, Park Y-C, Png G, Barysenka A, Fischer I, Bjørnland T, Southam L, Suveges D,
37 Neumeyer S, Rayner NW. Whole-genome sequencing analysis of the cardiometabolic proteome.
38 *Nature communications*. 2020;11(1):1-9.
- 39 52. Yang C, Farias FH, Ibanez L, Suhy A, Sadler B, Fernandez MV, Wang F, Bradley JL, Eiffert
40 B, Bahena JA. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins
41 implicated in neurological disorders. *Nature neuroscience*. 2021;24(9):1302-12.
- 42 53. Rücker G, Schwarzer G, Carpenter JR, Binder H, Schumacher M. Treatment-effect estimates
43 adjusted for small-study effects via a limit meta-analysis. *Biostatistics*. 2011;12(1):122-42.
- 44 54. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R,
45 Karlsson A, Santos R. The druggable genome and support for target identification and validation in
46 drug development. *Science translational medicine*. 2017;9(383):eaag1166.
- 47

1 **Table 1. Positive controls and repurposing opportunities: prioritised proteins affected by**
 2 **approved drug compounds.**
 3
 4

PROTEIN	UNIPROT ID	DRUGGABILITY*	METABOLITE CLASS(ES)*	NO. BREAKDOWN PRODUCTS*	BREAKDOWN PRODUCT EFFECT*	CARDIAC EFFECT*	OUTCOME	NO. DRUGS*	CARDIAC INDICATION AND/OR SIDE EFFECT*	CARDIAC INDICATION(S)	CARDIAC SIDE EFFECT(S)	DRUG NAME(S)
ACES	P22303	Drugged	Xenobiotics, Lipid	2	Mixed	1.09 (1.05; 1.13)	AF	23	Yes	Heart failure, Blood pressure disorders	See Appendix Table S7	See Appendix Table S7
ACES			Xenobiotics, Unclassified	2	Mixed	1.06 (1.04; 1.08)	HF					See Appendix Table S7 Deslanoside, Digoxin, Acetyldigoxin, Istaroxime, Lanatoside c, Omeprazole, Pantoprazole
ATL B2	P14415	Drugged	Unclassified	1	Increasing	0.79 (0.72; 0.87)	HCM	9	Yes	See Appendix Table S7	Arrhythmias, Cardiac conduction disorder	Lanatoside c, Omeprazole, Pantoprazole
DPEP1	P16444	Drugged	Amino Acid, Unclassified, Peptide	5	Mixed	0.97 (0.96; 0.98)	AF	2	Yes	Endocarditis	See Appendix Table S7	Cilastatin sodium, Cilastatin
EG LN1	Q9GZT9	Drugged	Xenobiotics	1	Increasing	0.88 (0.84; 0.92)	AF	9	Yes	See Appendix Table S7	-	Vadadustat, Enarodustat, Molidustat, Roxadustat, Daprodustat, Oxygen, Ascorbic acid, Citric acid, Fumaric acid
ICAM1	P05362	Drugged	Xenobiotics, Unclassified	2	Mixed	1.10 (1.06; 1.14)	HCM	6	Yes	See Appendix Table S7	-	Enlimomab pegol Bi-505, Enlimomab, Lovastatin, Lifitegrast, Dexamethasone
ICAM1			Xenobiotics	1	Decreasing	1.02 (1.01; 1.03)	HF					Enlimomab pegol Bi-505, Enlimomab, Lovastatin, Lifitegrast, Dexamethasone
MANBA	O00462	Drugged	Lipid	1	Increasing	1.07 (1.06; 1.08)	AF	1	Yes	Fabry disease	-	Migalastat
MET	P08581	Drugged	Peptide	1	Increasing	0.92 (0.88; 0.95)	AF	98	Yes	See Appendix Table S7	Qt interval prolongation, Arrhythmias, Heart failure	See Appendix Table S7
NQO1	P15559	Drugged	Unclassified	1	Increasing	0.97 (0.96; 0.98)	HF	4	Yes	Thrombosis	-	Vatiquone, Hydrogen peroxide, Dicumarol, Menadione
NQO2	P16083	Drugged	Amino Acid	1	Increasing	0.95 (0.93; 0.97)	HF	64	Yes	See Appendix Table S7	-	See Appendix Table S7
NTRK3	Q16288	Drugged	Unclassified	1	Increasing	0.73 (0.65; 0.83)	HCM	38	Yes	Pulmonary hypertension, Blood pressure disorders, Thrombosis	Qt interval prolongation, Heart failure, Blood pressure disorders	See Appendix Table S7
OLA1	Q9NTK5	Drugged	Unclassified	1	Increasing	0.81 (0.77; 0.85)	AF	47	Yes	See Appendix Table S7	-	See Appendix Table S7
RET	P07949	Drugged	Unclassified	1	Decreasing	0.97 (0.96; 0.98)	HF	75	Yes	See Appendix Table S7	Blood pressure disorders, Coronary heart disease	See Appendix Table S7
TEC	P42680	Drugged	Amino Acid	1	Increasing	0.87 (0.83; 0.90)	AF	61	Yes	See Appendix Table S7	-	See Appendix Table S7
TRY3	P35030	Drugged	Xenobiotics, Amino Acid	2	Mixed	0.92 (0.90; 0.94)	AF	15	Yes	See Appendix Table S7	-	See Appendix Table S7
TRYB1	Q15661	Drugged	Amino Acid, Unclassified	2	Increasing	1.02 (1.01; 1.03)	AF	1	Yes	Coronary heart disease, Heart failure, Blood pressure disorders	-	Arginine
UD11	P22309	Drugged	Peptide	1	Decreasing	2.87 (1.97; 4.17)	DCM	76	Yes	See Appendix Table S7	-	See Appendix Table S7
ADHL B	P00326	Drugged	Unclassified	1	Decreasing	1.14 (1.08; 1.20)	HF	2	No	-	-	Nitrofurantoin, Fomepizole
CAN2	P17655	Drugged	Unclassified	1	Decreasing	0.57 (0.46; 0.70)	HCM	2	No	-	-	Bortezomib, Carfilzomib
ENTP5	O75356	Drugged	Xenobiotics	1	Increasing	0.89 (0.86; 0.93)	AF	1	No	-	-	Anthralin
LYAM2	P16581	Drugged	Xenobiotics	1	Decreasing	1.25 (1.17; 1.33)	AF	4	No	-	-	Rivipansel, Cdp-850, Uproleselan, Bimosiromase

1
2
3
4
5
6
7
8
9
10
11
12
13

N.B. Characteristics of drugged prioritised proteins and urinary breakdown products associated with one or more cardiac disease(s). Cardiac effect estimates were obtained from *cis* Mendelian randomisation and are presented as odds ratios representing the effect of a one SD increase in protein levels, along with corresponding confidence intervals. The breakdown product effect indicates whether the breakdown product's effect on cardiac disease is risk-increasing or risk-decreasing, based on *cis* Mendelian randomisation. Druggability was determined based on ChEBML and the British National Formulary. Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy, HF = heart failure. More details can be found in Appendix Tables S6, S7.

1 **Figure legends (main figures)**

2

3 **Figure 1. Flowchart of the main steps of this study**

4 Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy,
5 HF = heart failure.

6

7 **Figure 2. A triangulation diagram illustrating an example of a triangulated association – with directional
8 concordance – between a protein and its effects on urinary breakdown product values and cardiac disease**

9 N.B. The plus symbol (in red) represents a positive association. The minus symbol (in blue) represents a
10 negative association (a risk-decreasing effect). Directional concordance is achieved when the direction of effects
11 aligns consistently, whether increasing or decreasing.

12

13 **Figure 3. Urinary breakdown products associated with at least one cardiac outcome, presented per
14 cardiac outcome**

15 N.B. Presented p-values are corresponding to effect estimates obtained from Mendelian randomisation analyses
16 leveraging genetic data on urinary breakdown products and cardiac diseases. Significant associations after
17 multiplicity correction are indicated by a star, non-significant associations by a dot. The top row provides the
18 number of drugged and druggable proteins, sourced from BNF and ChEMBL. Genetic associations with the
19 cardiac outcomes were obtained from Nielsen *et al.* (60,620 AF cases)(16), from Shah *et al.* (47,309 HF
20 cases)(17), from Garnier *et al.* (2,719 DCM cases)(18), and from Zhou *et al.* (2,993 HCM cases)(19). Genetic
21 associations with urinary breakdown products are obtained from Schlosser *et al.*(n=1,627)(15). For more detailed
22 information, please refer to the Methods section and **Appendix Table S2**.

23 Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy,
24 HF = heart failure, MR = Mendelian randomisation.

25

26 **Figure 4. Cardiac mRNA expression of directionally concordant proteins affecting cardiac disease
27 presented as percentage of the total expression across all tissues.**

28 N.B. Proteins are identified by their Uniprot label. Proteins displayed in bold font indicate that they are
29 overexpressed in cardiac tissue compared to non-cardiac tissue. Data were sourced from the Human Protein
30 Atlas; please refer to the Methods section for more details.

1

2 **Figure 5. Forest plots of cardiac effects of drugged or druggable prioritised proteins, presented by cardiac**
3 **disease**

4 N.B. Point estimates are obtained from Mendelian randomisation analyses leveraging genetic data on plasma
5 proteins and cardiac diseases. The metabolite classes of the breakdown products affected by the protein and
6 concordantly associating with the cardiac diseases are indicated on the right y-axis. Genetic associations with the
7 cardiac outcomes were sourced from Nielsen *et al.* (60,620 AF cases)(16), from Shah *et al.* (47,309 HF
8 cases)(17), from Garnier *et al.* (2,719 DCM cases)(18), and from Zhou *et al.* (2,993 HCM cases)(19). For a more
9 detailed description, please refer to the Methods section. Full numerical results can be found in **Appendix**
10 **Tables S6, S7.**

11 Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HCM =
12 hypertrophic cardiomyopathy, HF = heart failure, OR = odds ratio.

13

14 **Figure 6. Forest plot of the cardiac effects of prioritised proteins associating with more than one cardiac**
15 **outcome**

16 N.B. Point estimates are obtained from Mendelian randomisation analyses leveraging genetic data on plasma
17 proteins and cardiac diseases. The metabolite classes of the breakdown products affected by the protein and
18 concordantly associating with each cardiac disease are indicated on the right y-axis. Genetic associations with
19 the cardiac outcomes were sourced from Nielsen *et al.* (60,620 AF cases)(16), from Shah *et al.* (47,309 HF
20 cases)(17), from Garnier *et al.* (2,719 DCM cases)(18), and from Zhou *et al.* (2,993 HCM cases)(19). For a more
21 detailed description, please refer to the Methods section. Full numerical results can be found in **Appendix Table**
22 **S6.**

23 Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HCM =
24 hypertrophic cardiomyopathy, HF = heart failure, OR = odds ratio.

25

Step 1
Genome-wide MR

Urinary breakdown products
(n = 954)

Schlusser et al. (n = 1,627)

Cardiac outcomes:
AF, HF, DCM, HCM

AF: Nielsen et al. (60,620 cases) DCM: Garnier et al. (2,719 cases)
HF: Shah et al. (47,309 cases) HCM: Zhou et al. (2,993 cases)

Step 2
Cis-MR on urinary breakdown products

Unique urinary breakdown products associated with cardiac outcome
(n = 38)

Proteins
(n = 1,562 unique proteins)

deCODE (n = 35,559) AGES-Reykjavik (n = 5,368)
SCALLOP (n = 30,931) INTERVAL (n = 3,301)
Ahoia-OIE et al. (n = 8,293) Gilly et al. (n = 1,328)
Framingham (n = 6,861) Yang et al. (n = 636)

Step 3
Cis-MR on cardiac outcomes

Cardiac outcomes:
AF, HF, DCM, HCM

Proteins associated with a cardiac urinary breakdown product
(n = 709)

Step 4
Prioritising on concordance in direction, cardiac expression and druggability


Unique proteins associated with both a cardiac urinary breakdown product and cardiac outcome
(n = 235)

Unique proteins with a directionally concordant association with both a urinary breakdown product and cardiac outcome, expressed in cardiac tissue
(n = 91)

Drugged proteins
(n = 20)

Druggable proteins
(n = 12)


Not yet druggable proteins
(n = 59)



Metabolite class:

■ Amino Acid
 ■ Carbohydrate
 ■ Lipid
 ■ Peptide
 ■ Xenobiotics
 ■ Unclassified

Drugged/druggable proteins



Cysteinylglycine disulfide

4-guandinobutanoate

N-acetylcitrulline

Picolinate

Indoleacetylglutamine

N-acetylmethionine sulfoxide

1-methylhistamine

N-acetyl-3-methylhistidine

N-acetylputrescine

N-acetylariginine

N-acetylasparagine

N-acetyl-aspartyl-glutamate

N-acetylglucosamine/N-acetylgalactosamine

Nonenedioate

Glycochenodeoxycholate glucuronide

Glycochenolate sulfate

Prolylglycine

N-methylpipercolate

1-methylxanthine

3-hydroxyindolin-2-one sulfate

5-acetylamino-6-amino-3-methyluracil

5-acetylamino-6-formylamino-3-methyluracil

X - 24796

X - 12112

X - 19141

X - 24330

X - 23776

X - 15497

X - 23438

X - 18889

X - 24462

X - 24983

X - 12093


X - 21467


X - 13431





X - 12125

X - 24809

X - 12124






AF**DCM****HF****HCM**

Metabolite class:

■ Amino Acid
 ■ Lipid
 ■ Peptide
 ■ Xenobiotics
 ■ Unclassified



Metabolite class:

■ Amino Acid
 ■ Lipid
 ■ Xenobiotics
 ■ Unclassified